Stockreport

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

Axsome Therapeutics, Inc.  (AXSM) 
Last axsome therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: axsome.com
PDF Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS; p [Read more]